Prevalence of serum anti-myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) in patients with Graves' disease treated with propylthiouracil and thiamazole

Endocr J. 2002 Jun;49(3):329-34. doi: 10.1507/endocrj.49.329.

Abstract

Patients with Graves' disease (n = 61) treated with propylthiouracil (PTU) or thiamazole (MMI) were studied retrospectively to investigate differences in the prevalence of anti-myeloperoxidase anti-neutrophil cytoplasmic antibodies (MPO-ANCA) in relation to treatment with anti-thyroid drugs. The patients were divided into two groups: PTU-treated group (n = 32) and MMI-treated group (n = 29). There were no significant differences between the two groups in terms of age, gender distribution, or duration of treatment. In the PTU group, 8/32 (25%) patients were positive for MPO-ANCA, whereas in the MMI group, 1/29 (3.4%) patients were positive. There were no significant differences in age, duration, or dosage between the MPO-ANCA positive and negative patients. Most of the MPO-ANCA positive patients were asymptomatic, except for two patients in whom rheumatic arthritis or membranous glomerulonephritis developed. None of the MPO-ANCA positive patients were diagnosed as having classical ANCA-associated vasculitis. Thus, there is a high frequency of MPO-ANCA in patients with Graves' disease treated with PTU, compared with patients treated with MMI, although classical ANCA-associated vasculitis develops in only a few MPO-ANCA positive patients.

MeSH terms

  • Adult
  • Antibodies / blood*
  • Antibodies, Antineutrophil Cytoplasmic / blood*
  • Antithyroid Agents / therapeutic use*
  • Female
  • Graves Disease / blood
  • Graves Disease / drug therapy*
  • Graves Disease / immunology*
  • Humans
  • Male
  • Methimazole / therapeutic use*
  • Middle Aged
  • Peroxidase / immunology*
  • Propylthiouracil / therapeutic use*

Substances

  • Antibodies
  • Antibodies, Antineutrophil Cytoplasmic
  • Antithyroid Agents
  • Methimazole
  • Propylthiouracil
  • Peroxidase